Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J Zarnestra Slated For Oncologic Drugs Advisory Committee Review May 5

This article was originally published in The Pink Sheet Daily

Executive Summary

The oral farnesyl transferase inhibitor has a user fee date of June 29 for treatment of newly diagnosed acute myeloid leukemia in patients aged 65 years and older. The tipifarnib NDA is based on Phase II non-survival data; a Phase III trial is underway.

You may also be interested in...

J&J Completes Tipifarnib Submission For Leukemia Under Pilot 1 Program

The oral oncologic, known by the proposed trade name Zarnestra, could be approved by the end of the first half based on J&J's filing under the continuous marketing application pilot program and an expected six-month review. Submission is premised on Phase II response data.

Spectrum’s Iso-Vorin Could Clear FDA For Osteosarcoma By First Quarter

The Irvine, Calif., firm also plans sNDAs for a colorectal cancer claim and an oral formulation of the leucovorin relative.

Thelin's Third "Approvable" Letter Recommends Additional Clinical Trial

Encysive may be forced to make "significant reductions" to infrastructure and workforce, firm says June 15.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts